신경근 질환 시장 보고서(2026년)

Neuromuscular disorders are a group of medical conditions that impact the nerves and muscles, causing weakness, loss of movement, or impaired function. They arise when communication between the nervous system and muscles is disrupted due to genetic, autoimmune, or degenerative factors. These disorders often worsen over time and require continuous medical management, therapy, and supportive care.

The key disease categories of neuromuscular disorders include SMA, ALS, DMD, myasthenia gravis, and others. SMA is a genetic disease causing progressive motor neuron loss and muscle weakness. Product types include drugs, biologics, diagnostics, and assistive devices. Routes include oral, injectable, and others. Treatments include gene therapy, drug therapy, RNA-based therapy, enzyme replacement, rehabilitation, and respiratory care.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the neuromuscular disorders market by increasing costs of imported biologics, gene therapy components, diagnostic instruments, and assistive medical devices. north america and europe are significantly affected due to reliance on specialized pharmaceutical imports, while asia-pacific faces pricing pressure on advanced treatment solutions. these tariffs are increasing therapy costs and impacting patient access. however, they are also supporting domestic biopharmaceutical manufacturing, local diagnostic development, and regional innovation in rare disease treatments.

The neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides neuromuscular disorders market statistics, including neuromuscular disorders industry global market size, regional shares, competitors with a neuromuscular disorders market share, detailed neuromuscular disorders market segments, market trends and opportunities, and any further data you may need to thrive in the neuromuscular disorders industry. This neuromuscular disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuromuscular disorders market size has grown strongly in recent years. It will grow from $8.31 billion in 2025 to $8.98 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing prevalence of genetic neuromuscular conditions, rising awareness about early diagnosis and treatment options, growing demand for effective therapies for rare disorders, increasing research initiatives in muscular dystrophy and ALS, and rising adoption of advanced diagnostic technologies.

The neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $12.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising patient advocacy and support group activities, growing demand for biologics and gene therapies, increasing recognition of neuromuscular disorders in pediatrics, rising government initiatives for rare disease management, and growing emphasis on home-based care and rehabilitation services. Major trends in the forecast period include advancement in gene-editing technologies for targeted therapies, innovation in RNA-based treatment platforms, integration of AI for faster neuromuscular diagnosis, advancement in stem-cell-based regenerative treatments, and innovation in wearable devices for continuous patient monitoring.

The growing demand for personalized medicine is expected to drive the growth of the neuromuscular disorders market in the coming years. Personalized medicine is an approach that tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. This demand is rising due to advancements in genomic technologies, which enable precise identification of genetic variations and the development of targeted therapies. Personalized medicine enhances the management of neuromuscular disorders by customizing treatments according to individual genetic, molecular, and physiological profiles, improving patient outcomes through targeted therapies, optimized efficacy, and reduced adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from 12 approvals in 2022. Consequently, the rising demand for personalized medicine is fueling the growth of the neuromuscular disorders market.

Leading companies in the neuromuscular disorders market are focusing on developing advanced therapies, such as gene replacement treatments, to target the underlying genetic causes of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy involves engineered biological products that deliver functional copies of defective genes to restore or improve muscle function in patients with inherited neuromuscular disorders, offering a potential one-time treatment that reduces the need for long-term chronic therapy. For example, in November 2025, Novartis, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve), the first and only gene replacement therapy for children aged two years and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in the survival motor neuron 1 (SMN1) gene. The therapy is designed to address the genetic cause of SMA with a single, fixed dose that does not require adjustments for body weight or age. Itvisma can improve motor function by replacing the SMN1 gene, potentially reducing the need for long-term medications used alongside existing treatments for this patient population.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed sum. This acquisition strengthened Novartis's RNA-based therapeutic capabilities by incorporating DTx's proprietary FALCON siRNA platform and advancing early-stage programs targeting neuromuscular disorders, including Charcot-Marie-Tooth disease type 1A. DTx Pharma Inc. is a US-based biotechnology company focused on developing siRNA therapies for neurological and neuromuscular conditions.

Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.

North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuromuscular disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuromuscular disorders market consists of revenues earned by entities through diagnostic testing, therapeutic interventions, genetic counseling, rehabilitation therapy, and long-term patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuromuscular Disorders Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neuromuscular disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuromuscular disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuromuscular disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Type: Spinal Muscular Atrophy (SMA); Amyotrophic Lateral Sclerosis (ALS); Duchenne Muscular Dystrophy (DMD); Myasthenia Gravis; Other Muscular Dystrophies
• 2) By Product Type: Pharmaceuticals; Biologics; Diagnostic Tools; Assistive Devices
• 3) By Route of Administration: Oral; Injectable; Other Route of Administrations
• 4) By Treatment: Gene Therapy; Drug Therapy; RNA-Based Therapy; Enzyme Replacement Therapy; Physical Therapy And Rehabilitation; Respiratory Care
• Subsegments:
• 1) By Spinal Muscular Atrophy: SMA Type 1; SMA Type 2; SMA Type 3; SMA Type 4; SMA with Respiratory Distress (SMARD)
• 2) By Amyotrophic Lateral Sclerosis: Sporadic ALS; Familial ALS; Limb-Onset ALS; Bulbar-Onset ALS; Respiratory-Onset ALS
• 3) By Duchenne Muscular Dystrophy: Early-Onset DMD; Late-Onset DMD; Exon Deletion Mutations; Exon Duplication Mutations; Point Mutations
• 4) By Myasthenia Gravis: Generalized Myasthenia Gravis; Ocular Myasthenia Gravis; Seropositive MG; MuSK-Positive MG; Seronegative MG
• 5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD); Congenital Muscular Dystrophies; Myotonic Dystrophy
• Companies Mentioned: AbbVie Inc.; Novartis AG; Takeda Pharmaceutical Company Limited; The Trustees of the University of Pennsylvania; Biogen Inc.; Sarepta Therapeutics Inc.; argenx SE; PTC Therapeutics Inc.; Catalyst Pharmaceuticals Inc.; Mayo Clinic Laboratories; Fulgent Genetics Inc.; Dyne Therapeutics Inc.; The Regents of the University of California; GeneDx LLC; PepGen Inc.; Centogene N.V.; Scholar Rock Holding Corporation; Solid Biosciences Inc.; Vita Therapeutics Inc.; NMD Pharma A/S; Cytokinetics Incorporated; Sudo Biosciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Neuromuscular Disorders Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Neuromuscular Disorders Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Neuromuscular Disorders Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Neuromuscular Disorders Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Gene-Based Therapies
  • 4.2.2 Rising Use Of Advanced Diagnostic Tools
  • 4.2.3 Growing Focus On Multidisciplinary Care Approaches
  • 4.2.4 Expansion Of Supportive And Assistive Technologies
  • 4.2.5 Enhanced Emphasis On Early Diagnosis

5. Neuromuscular Disorders Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Neurology Clinics
• 5.3 Rehabilitation Centers
• 5.4 Research Institutions
• 5.5 Home Healthcare Providers

6. Neuromuscular Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neuromuscular Disorders Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Neuromuscular Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Neuromuscular Disorders Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Neuromuscular Disorders Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Neuromuscular Disorders Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neuromuscular Disorders Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neuromuscular Disorders Market Segmentation

• 9.1. Global Neuromuscular Disorders Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies
• 9.2. Global Neuromuscular Disorders Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices
• 9.3. Global Neuromuscular Disorders Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Other Route of Administrations
• 9.4. Global Neuromuscular Disorders Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care
• 9.5. Global Neuromuscular Disorders Market, Sub-Segmentation Of Spinal Muscular Atrophy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)
• 9.6. Global Neuromuscular Disorders Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS
• 9.7. Global Neuromuscular Disorders Market, Sub-Segmentation Of Duchenne Muscular Dystrophy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations
• 9.8. Global Neuromuscular Disorders Market, Sub-Segmentation Of Myasthenia Gravis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG
• 9.9. Global Neuromuscular Disorders Market, Sub-Segmentation Of Other Muscular Dystrophies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy

10. Neuromuscular Disorders Market Regional And Country Analysis

• 10.1. Global Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neuromuscular Disorders Market

• 11.1. Asia-Pacific Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neuromuscular Disorders Market

• 12.1. China Neuromuscular Disorders Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neuromuscular Disorders Market

• 13.1. India Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neuromuscular Disorders Market

• 14.1. Japan Neuromuscular Disorders Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neuromuscular Disorders Market

• 15.1. Australia Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neuromuscular Disorders Market

• 16.1. Indonesia Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neuromuscular Disorders Market

• 17.1. South Korea Neuromuscular Disorders Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neuromuscular Disorders Market

• 18.1. Taiwan Neuromuscular Disorders Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neuromuscular Disorders Market

• 19.1. South East Asia Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neuromuscular Disorders Market

• 20.1. Western Europe Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neuromuscular Disorders Market

• 21.1. UK Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neuromuscular Disorders Market

• 22.1. Germany Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neuromuscular Disorders Market

• 23.1. France Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neuromuscular Disorders Market

• 24.1. Italy Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neuromuscular Disorders Market

• 25.1. Spain Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neuromuscular Disorders Market

• 26.1. Eastern Europe Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neuromuscular Disorders Market

• 27.1. Russia Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neuromuscular Disorders Market

• 28.1. North America Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neuromuscular Disorders Market

• 29.1. USA Neuromuscular Disorders Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neuromuscular Disorders Market

• 30.1. Canada Neuromuscular Disorders Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neuromuscular Disorders Market

• 31.1. South America Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neuromuscular Disorders Market

• 32.1. Brazil Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neuromuscular Disorders Market

• 33.1. Middle East Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neuromuscular Disorders Market

• 34.1. Africa Neuromuscular Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Neuromuscular Disorders Market, Segmentation By Disease Type, Segmentation By Product Type, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neuromuscular Disorders Market Regulatory and Investment Landscape

36. Neuromuscular Disorders Market Competitive Landscape And Company Profiles

• 36.1. Neuromuscular Disorders Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Neuromuscular Disorders Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Neuromuscular Disorders Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. The Trustees of the University of Pennsylvania Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Neuromuscular Disorders Market Other Major And Innovative Companies

• Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S

38. Global Neuromuscular Disorders Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Neuromuscular Disorders Market

40. Neuromuscular Disorders Market High Potential Countries, Segments and Strategies

• 40.1 Neuromuscular Disorders Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Neuromuscular Disorders Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Neuromuscular Disorders Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer